| MeSH term | MeSH ID | Detail |
|---|---|---|
| Breast Neoplasms | D001943 | 24 associated lipids |
| Lung Neoplasms | D008175 | 171 associated lipids |
| Pancreatic Neoplasms | D010190 | 77 associated lipids |
| Colonic Neoplasms | D003110 | 161 associated lipids |
| Mammary Neoplasms, Experimental | D008325 | 67 associated lipids |
| Body Weight | D001835 | 333 associated lipids |
| Prostatic Neoplasms | D011471 | 126 associated lipids |
| Melanoma | D008545 | 69 associated lipids |
| Brain Diseases | D001927 | 27 associated lipids |
| Leukemia P388 | D007941 | 43 associated lipids |
MAYTANSINE
MAYTANSINE is a lipid of Polyketides (PK) class. Maytansine is associated with abnormalities such as Myelosuppression and BOSLEY-SALIH-ALORAINY SYNDROME. The involved functions are known as Mutation, Agent, Polymerization, Cell Cycle Arrest and Drug Kinetics. Maytansine often locates in Cytoplasm, Hepatic, Lysosomes, Cell surface and Microtubules. The associated genes with MAYTANSINE are ABCB1 gene, HM13 gene, CNN1 gene, CYP2C8 gene and CYP2D6 gene. The related lipids are Valerates. The related experimental models are Xenograft Model.
Cross Reference
Introduction
To understand associated biological information of MAYTANSINE, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with MAYTANSINE?
MAYTANSINE is suspected in Myelosuppression, BOSLEY-SALIH-ALORAINY SYNDROME and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with MAYTANSINE
PubChem Associated disorders and diseases
What pathways are associated with MAYTANSINE
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with MAYTANSINE?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with MAYTANSINE?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with MAYTANSINE?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with MAYTANSINE?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with MAYTANSINE?
Xenograft Model
Xenograft Model are used in the study 'IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.' (Ab O et al., 2015).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with MAYTANSINE
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Isakoff SJ and Baselga J | Trastuzumab-DM1: building a chemotherapy-free road in the treatment of human epidermal growth factor receptor 2-positive breast cancer. | 2011 | J. Clin. Oncol. | pmid:21172881 |
| Burris HA et al. | Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. | 2011 | J. Clin. Oncol. | pmid:21172893 |
| Allison M | Can cancer clinical trials be fixed? | 2011 | Nat. Biotechnol. | pmid:21221090 |
| Yang H et al. | Megakaryocyte lineage-specific class VI β-tubulin suppresses microtubule dynamics, fragments microtubules, and blocks cell division. | 2011 | Cytoskeleton (Hoboken) | pmid:21309084 |
| Sun X et al. | Design of antibody-maytansinoid conjugates allows for efficient detoxification via liver metabolism. | 2011 | Bioconjug. Chem. | pmid:21391620 |
| Kellogg BA et al. | Disulfide-linked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage. | 2011 | Bioconjug. Chem. | pmid:21425776 |
| Lopus M | Antibody-DM1 conjugates as cancer therapeutics. | 2011 | Cancer Lett. | pmid:21481526 |
| Edwards A et al. | Combinatorial effect of maytansinol and radiation in Drosophila and human cancer cells. | 2011 | Dis Model Mech | pmid:21504911 |
| Barok M et al. | Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo. | 2011 | Breast Cancer Res. | pmid:21510863 |
| Zhao RY et al. | Synthesis and evaluation of hydrophilic linkers for antibody-maytansinoid conjugates. | 2011 | J. Med. Chem. | pmid:21517041 |
| Lapusan S et al. | Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia. | 2012 | Invest New Drugs | pmid:21519855 |
| Olson EM et al. | Responses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancer. | 2012 | Ann. Oncol. | pmid:21531783 |
| Wu Y et al. | N-methylation of the amide bond by methyltransferase asm10 in ansamitocin biosynthesis. | 2011 | Chembiochem | pmid:21681880 |
| Beck A et al. | World Antibody Drug Conjugate Summit Europe: February 21-23, 2011; Frankfurt, Germany. | 2011 Jul-Aug | MAbs | pmid:21691144 |
| Hinow P et al. | Modeling the effects of drug binding on the dynamic instability of microtubules. | 2011 | Phys Biol | pmid:21836336 |
| Fishkin N et al. | A novel pathway for maytansinoid release from thioether linked antibody-drug conjugates (ADCs) under oxidative conditions. | 2011 | Chem. Commun. (Camb.) | pmid:21874179 |
| Jia Y and Zhong JJ | Enhanced production of ansamitocin P-3 by addition of Mg2+ in fermentation of Actinosynnema pretiosum. | 2011 | Bioresour. Technol. | pmid:21907573 |
| Gupta M et al. | Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer. | 2012 | J Clin Pharmacol | pmid:21953571 |
| Tuma RS | Enthusiasm for antibody-drug conjugates. | 2011 | J. Natl. Cancer Inst. | pmid:21972230 |
| Mathew J and Perez EA | Trastuzumab emtansine in human epidermal growth factor receptor 2-positive breast cancer: a review. | 2011 | Curr Opin Oncol | pmid:21986845 |